Clin2
NCT06158490Likely a fitEnrolling by invitation

JYP0061 tablet for moderate to severe eczema

Moderate-to-severe Atopic Dermatitis

Treatments studied

Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.

This trial tests a new tablet called JYP0061 for people with moderate to severe atopic dermatitis (eczema) that has lasted at least a year. It aims to see if the drug is safe and effective in reducing symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
120 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You weigh at least 40 kg (about 88 lbs).
  • You have had moderate to severe atopic dermatitis (eczema) for at least one year.
  • You are willing to use only non-medicated moisturizers and other allowed treatments during the study.
  • You do not have any other skin conditions or infections in the eczema area, and no weakened immune system.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07370909Recruiting· Phase 3
Oral LW402 for moderate-to-severe eczema

This trial tests an oral pill called LW402 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug is safe and effective at reducing skin symptoms.

Beijing
NCT07465120Not yet recruiting· Phase 2
Testing CMS-D001 for moderate to severe eczema

This study tests a new medicine called CMS-D001 for adults with moderate to severe eczema (atopic dermatitis) that hasn't improved enough with standard creams. Participants will receive either CMS-D001 or a placebo to see if it helps reduce itching and skin symptoms.

Beijing, Beijing Municipality
NCT06723080Recruiting· Phase 3
Oral VC005 for moderate to severe eczema

This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.

Nanjing, Jiangsu
NCT07558668Recruiting· Phase 1
Testing SYX-5219 for atopic dermatitis in healthy people and patients

This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.

Arkansas City, Arkansas
NCT07180511Enrolling by invitation· Phase 3
A study of QY201 tablets for moderate to severe eczema

This trial tests a new pill called QY201 for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. It aims to see if QY201 can help control itching and skin inflammation.

Hangzhou, Zhejiang
NCT07175233Not yet recruiting· Phase 2
Study of SIM0278 for moderate to severe eczema

This trial tests an experimental drug called SIM0278 for people with moderate to severe atopic dermatitis (eczema). It aims to see if the drug can reduce skin symptoms and is safe to use.

Hangzhou

Hear when a new Moderate to Severe Atopic Dermatitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.